Residency · Milwaukee, WI
Sponsored by Medical College of Wisconsin Affiliated Hospitals, Inc
North American Contact Dermatitis Group Patch Test Results: 2019-2020.
Dermatitis : contact, atopic, occupational, drug · 2023 · 104 citations · Jiade Yu
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial.
Journal of the American Academy of Dermatology · 2023 · 241 citations · Kenneth Gordon
Racial disparities in dermatology.
Archives of dermatological research · 2023 · 105 citations · Shanthi Narla
Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures.
Journal of the American Academy of Dermatology · 2021 · 228 citations · Kenneth Gordon
Stigmatization and Mental Health Impact of Chronic Pediatric Skin Disorders.
JAMA dermatology · 2024 · 54 citations · Kristen Holland
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
Lancet (London, England) · 2021 · 248 citations ·
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.
Lancet (London, England) · 2021 · 240 citations · Kenneth Gordon
Trends in the Prevalence of Methylchloroisothiazolinone/Methylisothiazolinone Contact Allergy in North America and Europe.
JAMA dermatology · 2023 · 47 citations · Jiade Yu